viewIQ-AI Ltd

IQ-AI reschedules Gallium Maltolate phase I clinical trial

The clinical evaluation has been pushed back to the fourth quarter after a change to encapsulation supplier


IQ-AI Limited said its Gallium Maltolate phase I clinical trial has been rescheduled for the fourth quarter rather than the summer as planned after a change to the trial agent's encapsulation supplier.

“While the selection and qualification process will result in a delay, securing and establishing a robust supply chain now will benefit subsequent trial phases and support high-volume production capacity,” investors were told.

“Overall, the trial continues to advance at a remarkable pace and has obtained all regulatory and institutional milestones as scheduled.”

The study will assess the potential of Gallium Maltolate to treat Glioblastoma Multiforme, the most common brain tumour.

Early success would see IQ-AI apply for orphan drug status for its discovery, a process in the US that provides certain protections and can also potentially fast-track approval.

Quick facts: IQ-AI Ltd


Price: 7.25 GBX

Market Cap: £12.33 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Market Report: Global gloom turns FTSE red

FTSE 100 was affected by the overnight falls in the US and Asia and eased lower in opening trades. Mixed results from some heavyweights also weighed on the mood and London’s blue-chip index shed 10 to 5,570. British Airways owner IAG posted another huge loss and warned that it urgently needs...

on 10/30/2020

2 min read